DMA Diamedica Therapeutics

DiaMedica (TSX VENTURE:DMA) today announces that Dr. Alexi Savinov of The
Sanford Project has been invited to present a poster based on its late-breaking
abstract, detailing results of pre-clinical studies of DM-199 for the treatment
of Type 1 diabetes. The material will be presented December 4-9, 2011 at the
21st biennial World Diabetes Congress organized by the International Diabetes
Federation (IDF) in Dubai, United Arab Emirates.


The poster is entitled "Novel DM-199 compound provides potent protection against
diabetes development in non-obese diabetic (NOD) mouse model by modulating
autoimmunity."


The Sanford Project and DiaMedica previously announced high-level results that
DM-199 administration to NOD mice, the gold standard animal model for Type 1
diabetes, prevented the autoimmune attack and thereby the destruction of
insulin-producing beta cells in the pancreas which causes Type 1 diabetes. The
DM-199 program has now demonstrated efficacy in three critical areas of Type 1
diabetes treatment; immune therapy, beta cell therapy and glucose control. 


The research was a collaborative effort between DiaMedica and The Sanford
Project, a research initiative at Sanford Health which has the goal to research
and cure Type 1 diabetes. "We look forward to sharing greater details of the
extremely promising results of DM-199 treatment for Type 1 diabetes at the IDF
World Diabetes Congress," stated Dr. Alexei Savinov, MD, The Sanford Project. 


About The Sanford Project 

The Sanford Project is one of the four initiatives made possible through Denny
Sanford's transformational gift to Sanford Health in 2007. From its inception,
The Sanford Project was "designed for results." Sanford Health will combine
clinical components of patient care and science into one of the most promising
and fast-moving fields of research; regenerative medicine. Their goal is to
research and cure Type 1 diabetes, all in pursuit of a healthy future for our
children. For further information please visit www.sanfordproject.org.


About DiaMedica

DiaMedica is a biopharmaceutical company that has developed novel therapeutic
compounds aimed to improve the lives of patients with diabetes and other major,
medically-unmet diseases. DiaMedica's lead compound, DM-199, represents a novel
approach to treating Type 1 and Type 2 diabetes by demonstrating significant
results against three major aspects of these diseases: 1) halting the autoimmune
attack on beta cells; 2) proliferating insulin producing beta cells and 3)
improving glucose control. 


DiaMedica is also developing DM-204, a monoclonal antibody that inhibits the
enzyme glycogen synthase kinase 3 beta (GSK3B). In pre-clinical studies, DM-204
significantly improved glucose control and decreased blood pressure. 


The company is listed on the TSX Venture Exchange under the trading symbol 'DMA'. 

Caution Regarding Forward-Looking Information 

The statements made in this press release that are not historical facts contain
forward-looking information that involves risk and uncertainties. All
statements, other than statements of historical facts, which address DiaMedica's
expectations, should be considered forward-looking statements. Such statements
are based on management's exercise of business judgment as well as assumptions
made by and information currently available to management. When used in this
document, the words "may", "will", "anticipate", "believe", "estimate",
"expect", "intend" and words of similar import, are intended to identify any
forward-looking statements. You should not place undue reliance on these
forward-looking statements. These statements reflect a current view of future
events and are subject to certain risks and uncertainties as contained in the
Company's filings with Canadian securities regulatory authorities. Should one or
more of these risks or uncertainties materialize, or should underlying
assumptions prove incorrect, actual results could differ materially from those
anticipated in these forward-looking statements. The Company undertakes no
obligation, and does not intend, to update, revise or otherwise publicly release
any revisions to these forward-looking statements to reflect events or
circumstances after the date hereof, or to reflect the occurrence of any
unanticipated events. Although management believes that expectations are based
on reasonable assumptions, no assurance can be given that these expectations
will materialize.

DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jun 2024 to Jul 2024

DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jul 2023 to Jul 2024